Drug Profile
Ibudilast - MediciNova
Alternative Names: AV-411; Eyevinal; Ibinal; KC-404; Ketas; MN-166; PinatosLatest Information Update: 01 Apr 2024
Price :
$50
*
At a glance
- Originator Kyorin Pharmaceutical
- Developer Banyu; Columbia University; Kyorin Pharmaceutical; MediciNova; National Institute of Drug Abuse; National Institute of Neurological Disorders and Stroke; Senju Pharmaceutical; University Health Network; University of California at Los Angeles; University of Colorado at Boulder; University of New South Wales; University of Sydney
- Class 2 ring heterocyclic compounds; Analgesics; Anti-inflammatories; Antiallergics; Antiasthmatics; Antihyperglycaemics; Antineoplastics; Antiplatelets; Drug withdrawal therapies; Eye disorder therapies; Neuroprotectants; Non-opioid analgesics; Nootropics; Pyrazoles; Pyridines; Small molecules
- Mechanism of Action Astrocyte inhibitors; Cytokine modulators; Glial cell modulators; Leukotriene receptor antagonists; Macrophage migration inhibitory factor inhibitors; Nitric oxide synthase inhibitors; Phosphodiesterase 10A inhibitors; Phosphodiesterase 11A inhibitors; Toll-like receptor 4 antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Alcoholism; Neurological disorders; Opioid-related disorders; Substance-related disorders
Highest Development Phases
- Marketed Allergic conjunctivitis; Asthma; Cerebrovascular disorders
- Phase III Spinal cord disorders
- Phase II/III Amyotrophic lateral sclerosis; Post acute COVID 19 syndrome
- Phase II Alcoholism; Multiple sclerosis; Opioid-related disorders; SARS-CoV-2 acute respiratory disease; Substance-related disorders
- Phase I/II Chemotherapy-induced damage; Glioblastoma
- Phase I Adult respiratory distress syndrome; Cytokine release syndrome; Sepsis
- Preclinical Acute lung injury; Uveal melanoma
- Suspended Neuropathic pain
- No development reported Brain injuries; Globoid cell leukodystrophy; Headache
- Discontinued Diabetic neuropathies; Diabetic retinopathy
Most Recent Events
- 26 Mar 2024 MediciNova receives Notice of Allowance from the Japan Patent Office for ibudilast for the treatment of macular injury associated with progressive Multiple sclerosis in Japan
- 12 Mar 2024 Pharmacodynamics data from a preclinical study in Acute lung injury released by MediciNova
- 17 Jan 2024 MediciNova receives notice of grant for Ibudilast for the treatment of macular injury associated with progressive Multiple sclerosis in China